Psychiatric medication management for Boca Raton — residential-level optimization, 20 minutes away.

For adults in Boca Raton whose outpatient medication trials have stalled, RECO Immersive's Delray Beach residential campus is 11 miles north up Federal Highway — roughly a 20-minute drive from Mizner Park or Royal Palm Place. Psychiatry is delivered as a continuous residential presence: observed adherence, weekly lithium and valproate levels during titration, metabolic and EKG monitoring where indicated, and integrated coordination with concurrent rTMS or ketamine at RECO Health. Discharge includes a documented medication plan that transfers cleanly to outpatient care in Boca Raton.

From Boca Raton — whether that means Mizner Park, Royal Palm Place, Downtown Boca, Boca West, or the Highland Beach coastline — RECO Immersive’s Delray Beach residential campus sits about 11 miles north up Federal Highway, roughly a 20-minute drive. For adults whose depression, anxiety, PTSD, or bipolar disorder has stopped responding to outpatient medication trials, that proximity matters: residential-level pharmacology optimization becomes available without a temporary relocation, and family and outpatient prescribers stay involved rather than displaced. Psychiatric medication management at RECO Immersive is integrated into the daily residential treatment plan — not a weekly appointment squeezed between groups, but a continuous clinical presence with visit-anchored measurement, observed dosing, and the ability to titrate on the basis of response data rather than self-report at the next outpatient window.

What observed adherence and daily monitoring change

In outpatient practice, whether a client is actually taking sertraline, lithium, or aripiprazole exactly as prescribed is inferred from self-report, pharmacy fill records, and pill counts. In residential care, adherence is directly observed. That distinction is decisive for medications with narrow therapeutic windows — lithium and valproate in particular — where a trough level drawn 12 hours after a witnessed dose is a genuinely interpretable data point, and where a trough drawn after uncertain adherence is not.

The same principle applies to side-effect capture. When akathisia emerges on an antipsychotic titration, when SSRI-induced activation shows up in the first ten days of a sertraline start, when quetiapine sedation collides with daytime programming — the residential team sees it in real time and adjusts the regimen at the next round rather than waiting two weeks for the next outpatient visit, by which point the client has often already discontinued the trial on their own. Standardized measurement is built into the daily rhythm: PHQ-9 and GAD-7 at admission and repeated on a defined cadence, YBOCS for OCD presentations, ASRS where adult ADHD is on the differential, and PCL-5 for PTSD symptom tracking.

Comprehensive lab monitoring during the residential stay

Every admission opens with a baseline lab panel that many outpatient trials never collected in full: CBC, comprehensive metabolic panel, TSH with reflex, B12 and folate, vitamin D, fasting lipids, HbA1c, urine drug screen, and urine pregnancy testing where clinically indicated. That baseline is what makes subsequent medication decisions defensible — it establishes whether a thyroid contribution has been ruled out before a treatment-resistant depression label is applied, and whether a metabolic starting point has been documented before an atypical antipsychotic is introduced.

Medication-specific monitoring is then built into the residential cadence rather than negotiated around outpatient scheduling. Lithium levels are drawn weekly during titration and after any dose change; valproate levels follow the same rhythm. Metabolic panels are repeated at discharge for clients on olanzapine, quetiapine, or other second-generation antipsychotics with metabolic risk. EKGs are obtained where QTc-prolonging agents or cardiovascular history warrant them. The monitoring schedule is set by pharmacology, not by which day the client can get to a lab.

Coordination with concurrent interventional treatment

A substantial share of Immersive residents are candidates for interventional psychiatry running in parallel at RECO Health — rTMS delivered at 120% of motor threshold for 3,000 pulses per session over a standard six-week protocol, or intranasal esketamine and racemic ketamine infusions for treatment-resistant depression. When those tracks run concurrently, the psychiatry team runs both rather than negotiating across two independent prescribers with different chart access.

That integration shows up in specific decisions: keeping the oral antidepressant regimen stable and adherent during the acute TMS course so that response can be attributed correctly; timing medication adjustments around ketamine infusions so that dissociative effects and blood-pressure response remain interpretable; folding interventional treatment gains into the ongoing pharmacology plan rather than treating them as an unrelated event. For clients who arrive already on buprenorphine or naltrexone for a co-occurring substance use disorder, opioid agonist and antagonist therapy is continued and coordinated with the psychiatric regimen rather than paused.

The medication plan the client leaves with

Discharge from Immersive includes a documented medication plan the client can actually use: the current regimen with rationale for each agent, the specific target symptoms each medication is addressing, the monitoring schedule that has to continue after discharge, and the next-step contingencies if response plateaus. The plan is written to transfer cleanly — either to the RECO Health outpatient psychiatry team as part of a step-down PHP or IOP episode, or to a home-community prescriber the client already has in Boca Raton.

What matters clinically is that the client leaves knowing why they are on what they are on. When a Boca Raton primary care physician later asks why the client is on 900 mg of lithium plus 15 mg of aripiprazole plus 10 mg of buspirone, there is a coherent answer, a documented trial history, and a recommended next-visit focus. That handoff clarity is what makes the residential pharmacology gains hold once the client is back in outpatient care.

What to expect on the first psychiatric visit

The first psychiatric contact at Immersive is a full diagnostic interview, not a medication reconciliation appointment. It reviews prior trials with attention to what actually failed — inadequate dose, inadequate duration, intolerable side effects, or genuine non-response — because those four categories drive very different next steps. It includes a structured assessment of trauma history using instruments like the PCL-5, a substance use history mapped to ASAM Criteria dimensions where relevant, and a screen for undiagnosed adult ADHD using the ASRS when the presentation warrants it.

Modalities running alongside pharmacotherapy — CBT for depression and anxiety, DBT for emotion dysregulation, EMDR and prolonged exposure for PTSD, ACT and motivational interviewing across presentations — are selected in the same treatment-planning meeting rather than referred out. That means the medication plan and the psychotherapy plan are built on a single case formulation, not stitched together from independent providers.

Insurance and admissions from Boca Raton

RECO Immersive works in-network or with out-of-network benefits from Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield plans. Admissions from Boca Raton typically begin with a phone verification of benefits, a clinical intake conversation, and a medical screen confirming that a residential level of care is clinically indicated under ASAM Criteria. When residential is not the right fit, the team refers to the appropriate step in the RECO Health continuum — PHP, IOP, or outpatient psychiatry — rather than admitting reflexively.

Serving residents of: Mizner Park, Royal Palm Place, Downtown Boca, Boca West, Highland Beach.